Clinical trials: Brain Age
Migraine
A Study to Test if Fremanezumab is Effective in Preventing Episodic Migraine in Patients 6 to 17 Years of Age
The primary objective of the study is to evaluate the efficacy of fremanezumab as compared to placebo for the preventive treatment of episodic migraine (EM).
- Trial name
- NCT04458857
- Testing
- Fremanezumab
- Where
- 89 sites in United States, Canada and 7 more
- Volunteers
- 235 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Epilepsy
Follow-up Trial to Evaluate Long-term Safety and Efficacy of Brivaracetam in Subjects Suffering From Epilepsy
This trial, evaluating the long-term safety and tolerability of brivaracetam, will give subjects suffering from epilepsy, who may have benefited from brivaracetam, the opportunity to continue the treatment.
- Trial name
- NCT00175916
- Testing
- Brivaracetam (ucb 34714)
- Where
- 153 sites in United States, Austria and 24 more
- Volunteers
- 853 people
- Sponsor
- UCB Pharma
Cerebral Palsy, Hypoxia-Ischemia, Brain
The TOBY Children Study
The aim of this study is to determine the efficacy of therapeutic hypothermia following perinatal asphyxia on neurological and neuropsychological outcomes and also to assess academic attainment and any additional health, societal…
- Trial name
- NCT01092637
- Where
- United Kingdom
- Volunteers
- 280 people
- Sponsor
- Imperial College London
Alzheimer Disease, Presbycusis
Age-related Hearing Loss and Lexical Disorders
In France, Alzheimer's disease accounts for 70 to 80% of the causes of neurocognitive disorders, i.e. 600,000 to 800,000 patients.
- Conditions
- Alzheimer Disease, Presbycusis, Lexical Syntactic Disorder
- Trial name
- LOOP (NCT03638323)
- Testing
- Speech therapy
- Where
- France
- Volunteers
- 46 people
- Sponsor
- Groupe Hospitalier de la Rochelle Ré Aunis
Infant, Newborn, Hypoxia, Brain
Optimizing (Longer, Deeper) Cooling for Neonatal Hypoxic-Ischemic Encephalopathy(HIE)
The Optimizing Cooling trial will compare four whole-body cooling treatments for infants born at 36 weeks gestational age or later with hypoxic-ischemic encephalopathy: (1) cooling for 72 hours to 33.5°C; (2) cooling for 120…
- Conditions
- Infant, Newborn, Hypoxia, Brain, Hypoxia-Ischemia, Brain, Encephalopathy, Hypoxic-Ischemic
- Trial name
- NCT01192776
- Testing
- Whole-body Cooling
- Where
- 19 sites in United States
- Volunteers
- 364 people
- Sponsor
- NICHD Neonatal Research Network
Urea Cycle Disorder
A Study of the Safety, Efficacy and Pharmacokinetics of Glycerol Phenylbutyrate in Pediatric Subjects Under 2 Years of Age With Urea Cycle Disorders
This is an open-label study consisting of a transition period to RAVICTI, followed by a safety extension period for at least 6 months and up to 24 months of treatment with RAVICTI, depending on age at enrollment.
- Trial name
- NCT02246218
- Testing
- RAVICTI
- Where
- 17 sites in United States, Canada
- Volunteers
- 27 people
- Sponsor
- Amgen
Epilepsy, Generalized Tonic-Clonic Seizures
A Double-blind, Placebo-controlled Study of Levetiracetam in Epilepsy Patients With Generalized Tonic-clonic Seizures (Except Partial Seizures Evolving to Secondarily Generalized Seizures)
The purpose of this study is to evaluate the efficacy, safety and tolerability of levetiracetam treatment used as adjunctive therapy in Japanese and Chinese epilepsy patients aged ≥16 years and with uncontrolled Generalized…
- Trial name
- NCT01228747
- Testing
- Levetiracetam
- Where
- 58 sites in China, Japan
- Volunteers
- 361 people
- Sponsor
- UCB Japan Co. Ltd.
Cerebral Palsy, Spasticity
Dose-response Study of Efficacy and Safety of Botulinum Toxin Type A to Treat Spasticity of the Arm(s) or of Arm(s) and Leg(s) in Cerebral Palsy
The purpose of this study is to determine whether injections of Botulinum toxin type A into muscles of one or both arms alone or in combination with injections into one or both legs are effective and safe in treating…
- Trial name
- XARA (NCT02002884)
- Testing
- IncobotulinumtoxinA (8 Units per kg body weight), IncobotulinumtoxinA (6 Units per kg body weight), IncobotulinumtoxinA (2 Units per kg body weight)
- Where
- 32 sites in United States, Argentina and 4 more
- Volunteers
- 351 people
- Sponsor
- Merz Pharmaceuticals GmbH
Epilepsy, Partial Onset Seizures
An Open Label Study of Levetiracetam Monotherapy in Patients With Newly Diagnosed Focal Epilepsy
The purpose of this study is to evaluate the efficacy of Levetiracetam (LEV) used as monotherapy, with efficacy measured as 6-month seizure freedom at the last evaluated dose in the LEV 1000 mg/day to 2000 mg/day group, in newly…
- Trial name
- NCT01506882
- Testing
- Levetiracetam (LEV)
- Where
- 27 sites in Japan
- Volunteers
- 71 people
- Sponsor
- UCB Japan Co. Ltd.
Depression, Dementia
Prognosis of Depression in the Elderly (PRODE). A Multicentre, Longitudinal Study of Elderly Depressed Patients.
PRODE is a Norwegian multicentre study investigating the prognosis of depression in the elderly. The study has included 169 patients who will be followed with assessments after one and three years.
- Trial name
- PRODE (NCT01952366)
- Where
- Norway
- Volunteers
- 169 people, healthy volunteers welcome
- Sponsor
- Sykehuset Innlandet HF
Sphingomyelin Lipidosis
Safety, Tolerability, PK, and Efficacy Evaluation of Repeat Ascending Doses of Olipudase Alfa in Pediatric Patients <18 Years of Age With Acid Sphingomyelinase Deficiency
Primary Objective: To evaluate the safety and tolerability of olipudase alfa administered intravenously in pediatric participants every 2 weeks for 64 weeks.
- Trial name
- ASCEND-Peds (NCT02292654)
- Testing
- Olipudase alfa
- Where
- 6 sites in United States, Brazil and 4 more
- Volunteers
- 20 people
- Sponsor
- Genzyme, a Sanofi Company
Epilepsy
A Study With an Open-label Extension Phase to Evaluate the Effect of Perampanel (E2007) on Cognition, Growth, Safety, Tolerability, and Pharmacokinetics in Adolescents
This study is designed to investigate the short- and long-term effects of perampanel on cognition, growth, and development in adolescents.
- Trial name
- NCT01161524
- Testing
- Perampanel
- Where
- 37 sites in United States, Australia and 9 more
- Volunteers
- 133 people
- Sponsor
- Eisai Inc.
Tourette Syndrome
Pramipexole Pilot Phase II Study in Children and Adolescents With Tourette Disorder According to DSM-IV Criteria
A randomized, double-blind, placebo-controlled, flexible dose study to evaluate efficacy and safety of Pramipexole versus placebo for 6 weeks in children (age 6-17) diagnosed with Tourette Disorder according to DSM IV criteria.
- Trial name
- NCT00558467
- Testing
- pramipexole immediate release (IR)
- Where
- 16 sites in United States, Germany
- Volunteers
- 63 people
- Sponsor
- Boehringer Ingelheim
Migraine Disorders
A Study Using Botulinum Toxin Type A as Headache Prophylaxis in Adolescents With Chronic Migraine
To evaluate the efficacy and safety of Botulinum Toxin Type A versus placebo (normal saline) as headache prophylaxis in adolescents (children 12 to 17) with chronic migraine.
- Trial name
- NCT01662492
- Testing
- Botulinum toxin type A Dose 1, Botulinum toxin type A Dose 2
- Where
- 22 sites in United States
- Volunteers
- 125 people
- Sponsor
- Allergan
Epilepsy
This Trial, Evaluating the Long-term Safety and Tolerability of Brivaracetam Will Provide Subjects Suffering From Epilepsy, Who May Have Benefited From Brivaracetam as Adjunctive Treatment, the Opportunity to Receive Open Label Brivaracetam Treatment
This trial, evaluating the long-term safety and tolerability of brivaracetam will provide subjects suffering from epilepsy, who may have benefited from brivaracetam as adjunctive treatment, the opportunity to receive open label…
- Trial name
- NCT00150800
- Testing
- Brivaracetam
- Where
- 100 sites in United States, Australia and 4 more
- Volunteers
- 668 people
- Sponsor
- UCB PHARMA Inc. (US)
Epilepsy, Partial Seizures, Epilepsy, Primary Generalized Tonic-Clonic Seizures
A 12-Month Study To Evaluate The Safety And Tolerability Of Pregabalin As Add-On Therapy In Pediatric Subjects 1 Month To 16 Years Of Age With Partial Onset Seizures And Pediatric And Adult Subjects 5 To 65 Years Of Age With Primary Generalized Tonic-Clonic Seizures
Study A0081106 is a 12-month open-label study to evaluate the long term safety and tolerability of pregabalin as add-on therapy in pediatric subjects 1 month to 16 years of age with partial onset seizures and pediatric and adult…
- Trial name
- NCT01463306
- Testing
- Pregabalin
- Where
- 151 sites in United States, Belarus and 29 more
- Volunteers
- 605 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Infant, Newborn, Hypoxia, Brain
Preemie Hypothermia for Neonatal Encephalopathy
This study is a randomized, controlled trial to assess safety and effectiveness of whole body hypothermia for 72 hours in preterm infants 33-35 weeks gestational age (GA) who present at <6 hours postnatal age with moderate to…
- Conditions
- Infant, Newborn, Hypoxia, Brain, Hypoxia-Ischemia, Brain, Encephalopathy, Hypoxic-Ischemic
- Trial name
- NCT01793129
- Testing
- Hypothermia, Normothermic Control
- Where
- 18 sites in United States
- Volunteers
- 168 people
- Sponsor
- NICHD Neonatal Research Network
Influenza, Pneumonia
Flublok v. Standard Dose Vaccine Effectiveness Among Kaiser Permanente Northern California Adults 18-64 Years
The overall objective of this study is to describe the effectiveness of Flublok Quadrivalent vaccine compared to standard dose inactivated influenza vaccine (SD-IIV) in adults 18 through 64 years of age.
- Conditions
- Influenza, Pneumonia, Lower Respiratory Tract Infection, Acute Myocardial Infarction
- Trial name
- NCT03694392
- Testing
- Flublok Quadrivalent, Standard Dose Inactivated Influenza Vaccine (SD-IIV)
- Where
- United States
- Volunteers
- 2,776,278 people, healthy volunteers welcome
- Sponsor
- Kaiser Permanente
Alzheimer's Disease
Efficacy and Safety of Plasma Exchange With 5% Albumin in Beta-amyloid Peptide Clearance in Cerebral Spinal Fluid
The purpose of this study was to evaluate the efficacy and safety of plasma exchange with 5% albumin in beta-amyloid peptide clearance in cerebrospinal fluid, and its effects in patients with mild-moderate Alzheimer's disease.
- Trial name
- NCT00742417
- Testing
- Albutein 5%, Control
- Where
- 4 sites in United States, Spain
- Volunteers
- 42 people
- Sponsor
- Instituto Grifols, S.A.
Epilepsy
A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Intravenous Brivaracetam in Subjects >= 1 Month to < 16 Years of Age With Epilepsy
The purpose of the study is to evaluate the pharmacokinetics (PK), safety, and tolerability of brivaracetam (BRV) administered intravenously (iv) in subjects >= 1 month to < 16 years of age with epilepsy.
- Trial name
- NCT03405714
- Testing
- Brivaracetam
- Where
- 17 sites in United States, Czechia and 5 more
- Volunteers
- 50 people
- Sponsor
- UCB Biopharma S.P.R.L.